Lexaria Bioscience (LEXX) Return on Equity ROE from the third quarter 2026 to third quarter 2025 and annually, average high and low, overall ranking from May 31 2026 to May 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Lexaria Bioscience Corp   (NASDAQ: LEXX)

Lexaria Bioscience 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Lexaria Bioscience in the third quarter 2026?
Lexaria Bioscience Corp recorded a cumulative net loss of $-8 million during 12 months ending in the third quarter 2026, resulting in a negative return on equity (ROE) of -171.3%.

Within the Major Pharmaceutical Preparations industry 299 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the second quarter 2026 from 85 to 3685.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (May 31 2026)
III. Quarter		 (Feb 28 2026)
II. Quarter		 (Nov 30 2025)
I. Quarter		 (Aug 31 2025)
IV. Quarter		 (May 31 2025)
III. Quarter
Y / Y Equity Change -8.29 % -8.14 % -51.85 % -66.02 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -8 -10 -11 -12 -11
Return On Equity (TTM) -171.3 % -206.19 % -226.78 % -199.15 % -157.36 %
LEXX's Total Ranking # 3685 # 85 # 3285 # 3312 # 3196
Equity (TTM) in Millions 5 6 5 3 5
Seq. Equity Change -23.7 % 37.29 % 73.8 % -49.62 % -23.58 %
Seq. Net Income Change - - - - -

Back to LEXX Management Effectiveness >> LEXX's 5 Years Annual ROE >> Compare LEXX ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 300
Sector # 639
Overall # 3685

Return On Equity Statistics
High Average Low
-10.08 %
-195.04 %
-988.36 %
(Nov 30 2021)   (Aug 31 2016)



  News about Lexaria Bioscience Corp Return on Equity ROE

Lexaria Bioscience Corp's Revolutionary Drug-Delivery System: The Future of Medical Breakthroughs and Profitability.

as Profitable: Lexaria Bioscience s Breakthrough Drug-Delivery System Revolutionizes Medical Treatments
Lexaria Bioscience Corp. (NASDAQ: LEXX) has recently revealed its groundbreaking proprietary drug-delivery system, which has the potential to revolutionize the way molecules enter the bloodstream and offer exciting new possibilities for GLP-1 Diabetes and weight-loss drugs. With this innovative technology, the company aims to address some of the most significant challenges in the pharmaceutical industry and open doors for revolutionary cures.
In the fourth quarter of 2023, Lexaria Bioscience Corp reported a cumulative net loss of $-8 million, resulting in a negative return on equity (ROE) of -195.66%. While this financial setback might seem concerning at first, it is crucial to assess its actual impact on the company and the long-term potential offered by its drug-delivery system.

Lexaria Bioscience Corp. Revolutionizes Drug Delivery for Type 2 Diabetes Treatment

Lexaria Bioscience Corp. (NASDAQ: LEXX) has recently announced an exciting breakthrough in drug delivery technology, elevating the efficacy and delivery of GLP-1 agonists through its proprietary platform. The company s achievements have been highlighted in an editorial published by NetworkNewsWire, a leading financial news and content distribution platform.
The innovative drug-delivery platform developed by Lexaria Bioscience Corp. has the potential to revolutionize the administration of GLP-1 agonists, a class of drugs used in the treatment of type 2 diabetes. By enhancing the delivery of these medications, the company aims to improve patient outcomes and offer a more convenient and effective solution for individuals suffering from this chronic condition.



LEXX Annual Return On Equity (Aug 31 2025)
2025		 (Aug 31 2024)
2024		 (Aug 31 2023)
2023		 (Aug 31 2022)
2022		 (Aug 31 2021)
2021
Total Equity in Millions 3 8 3 8 13
Y / Y Equity Change -66.02 % 185.78 % -64.89 % -41.57 % 426.28 %
Net Income in Millions -12 -6 -7 -7 -4
Y / Y Net Income Change - - - - -
Return On Equity -457.65 % -75.84 % -250.46 % -93.74 % -29.61 %

Back to LEXX Management Effectiveness >> LEXX's 5 Years Annual ROE >> Compare LEXX ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
LEXX's' Return on Equity at Yahoo Finance
LEXX's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for LEXX's Competitors
Subscribers only: Roe for Lexaria Bioscience 's Suppliers
Subscribers only: Return On Equity for LEXX's Customers




Companies with similar Return On Equity at May 31 2026, within Healthcare Sector ROE

Date modified: 2026-08-03T18:30:59+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.